Provided by Tiger Fintech (Singapore) Pte. Ltd.

Day One Biopharmaceuticals Inc.

7.22
-0.4900-6.36%
Post-market: 7.390.1700+2.35%16:53 EDT
Volume:934.43K
Turnover:6.75M
Market Cap:731.78M
PE:-7.05
High:7.70
Open:7.55
Low:7.06
Close:7.71
Loading ...

Day One Biopharm Price Target Maintained With a $36.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Apr

Promising Outlook for Day One Biopharmaceuticals: Buy Rating Driven by Ojemda’s Market Potential

TIPRANKS
·
03 Apr

Day One Biopharm Is Maintained at Buy by Goldman Sachs

Dow Jones
·
25 Mar

Buy Rating for Day One Biopharmaceuticals: Strong Financial Position and Strategic Growth Potential

TIPRANKS
·
11 Mar

High Growth Tech Stocks In The US With Promising Potential

Simply Wall St.
·
11 Mar

Day One Biopharm Is Maintained at Overweight by JP Morgan

Dow Jones
·
05 Mar

Day One Biopharmaceuticals, Inc. (DAWN): A Bull Case Theory

Insider Monkey
·
05 Mar

Day One Biopharma’s Earnings Call Highlights Growth and Challenges

TIPRANKS
·
28 Feb

Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations

Zacks
·
26 Feb

Promising Growth Potential for Day One Biopharmaceuticals Driven by Ojemda and FIREFLY-2 Trial

TIPRANKS
·
26 Feb

Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
26 Feb

Day One Biopharm Price Target Maintained With a $32.00/Share by Needham

Dow Jones
·
26 Feb

Oppenheimer Sticks to Their Hold Rating for Day One Biopharmaceuticals (DAWN)

TIPRANKS
·
26 Feb

Day One Biopharmaceuticals Reports Strong 2024 Results

TIPRANKS
·
26 Feb

Promising Growth and Strategic Positioning Justify Buy Rating for Day One Biopharmaceuticals

TIPRANKS
·
26 Feb

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
26 Feb

Day One Biopharmaceuticals Reports 2024 Financial Results

TIPRANKS
·
26 Feb

Day One Biopharmaceutical Q4 GAAP EPS $(0.69) Misses $(0.36) Estimate, Sales $29.21M Beat $27.79M Estimate

Benzinga
·
26 Feb

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

GlobeNewswire
·
26 Feb

Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates

Zacks
·
21 Feb